<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00204347</url>
  </required_header>
  <id_info>
    <org_study_id>RIS-DED-WTJ</org_study_id>
    <nct_id>NCT00204347</nct_id>
  </id_info>
  <brief_title>Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder</brief_title>
  <official_title>Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder: The UAB Borderline Rating Scale (BRS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Pharmaceutica N.V., Belgium</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <brief_summary>
    <textblock>
      The objective of Study A is to evaluate the efficacy of risperidone on the 4 behavioral
      dimensions of Berderline Personality Disorder (BPD)in an open label trial:mood swings,
      impulsivity, thing difficulties and disturbed relationships. The secondary objective of this
      study (Study B)is to validate a self-report measure of clinical symptoms specific to the
      treatment of patients with BPD, the UAB Borderline Rating Scale(BRS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study A: An open-label, prospective trial of the efficacy and safety of risperidone in the
      treatment of BPD.The study is 8 weeks in duration, with a screening visit and follow-up
      visits at the end of Weeks 1,2,3,4,6, and 8. 20 female patients, 19 years or older will be
      recruited. A full medical and psychiatric history will be taken and a physical exam will be
      performed by a sstudy physician. A psychosocial assessment will be conducted during the
      screen.

      Study B: The ofjective is to validate the UAB BRS by administering the BRS and other
      neuropsychological instruments as repeated measures over a 6 week period to 40 patients with
      BPD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Symptom Inventory</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Enjoyment and Satisfaction Questionnaire</measure>
  </secondary_outcome>
  <enrollment>20</enrollment>
  <condition>Borderline Personality Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of BPD

        Exclusion Criteria:

          -  Any other Axis I diagnosis except dysthymia, PTSD, or generalized anxiety
             disorder;substance abuse within a month; unstable medical illness.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Celia T. Huston, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>March 15, 2012</last_update_submitted>
  <last_update_submitted_qc>March 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Bobbie May</investigator_full_name>
    <investigator_title>Asst. Professor</investigator_title>
  </responsible_party>
  <keyword>risperidone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

